Latest news
25 items- PRPESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven CancersReport covers Silexion Therapeutics (NASDAQ:SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the company's impressive clinical achievements and unique approach alongside industry drivers including the increasing M&A activity in the space Silexion Therapeutics (NASDAQ:SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference (RNAi) therapies for KRAS-driven cancers. As a recently de-SPACed company following its merger with Moringa Acquisition Corp (NASDAQ:MACA), Silexion presents an interesting opportunity in the rap
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Moringa Acquisition CorpSCHEDULE 13G/A - Moringa Acquisition Corp (0001835416) (Subject)
- SECSEC Form 15-12G filed by Moringa Acquisition Corp15-12G - Moringa Acquisition Corp (0001835416) (Filer)
- SECMoringa Acquisition Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Moringa Acquisition Corp (0001835416) (Filer)
- SECSEC Form 25-NSE filed by Moringa Acquisition Corp25-NSE - Moringa Acquisition Corp (0001835416) (Subject)
- PRSilexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business CombinationMODI'IN, Israel and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Ltd. ("Silexion"), a clinical-stage, oncology-focused biotechnology company and Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa"), a publicly-traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination") with Biomotion Sciences (the "combined company"), a recently formed entity. The combined company's name is changing from Biomotion Sciences to "Silexion Therapeutics Corp", and its ordinary shares and warrants are expected to begin trading on Nasdaq under the tickers "SLXN" and "SLXNW", respectively, on August 16
- SECSEC Form 10-Q filed by Moringa Acquisition Corp10-Q - Moringa Acquisition Corp (0001835416) (Filer)
- SECMoringa Acquisition Corp filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Moringa Acquisition Corp (0001835416) (Filer)
- SECSEC Form DEFM14A filed by Moringa Acquisition CorpDEFM14A - Moringa Acquisition Corp (0001835416) (Filer)
- SECMoringa Acquisition Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Moringa Acquisition Corp (0001835416) (Filer)
- SECSEC Form 10-Q filed by Moringa Acquisition Corp10-Q - Moringa Acquisition Corp (0001835416) (Filer)
- SECMoringa Acquisition Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Moringa Acquisition Corp (0001835416) (Filer)
- SECSEC Form 10-K filed by Moringa Acquisition Corp10-K - Moringa Acquisition Corp (0001835416) (Filer)
- SECMoringa Acquisition Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Moringa Acquisition Corp (0001835416) (Filer)
- SECMoringa Acquisition Corp filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Moringa Acquisition Corp (0001835416) (Filer)
- NEWSSilexion, A Clinical-Stage, Oncology-Focused Biotechnology Company, To Become Publicly Traded Via Business Combination With Moringa Acquisition CorpSilexion's first generation product, Loder™, successfully tested in a multinational Phase 2a clinical trial in patients with non-resectable pancreatic cancer which harbors an oncogene believed to be a major driver of the cancerIn combination with chemotherapy, Loder resulted in a median overall survival (OS) advantage of 9.3 months over chemotherapy alone (22.7 vs 13.4 months)Modi'in, Israel and New York, New York, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa"), a special purpose acquisition company, today announced it has entered into a business combination agreement with Silexion Ltd. ("Silexion"), a clinical-stage, oncology-focused biotechnology compa
- PRSilexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition CorpSilexion's first generation product, Loder™, successfully tested in a multinational Phase 2a clinical trial in patients with non-resectable pancreatic cancer which harbors an oncogene believed to be a major driver of the cancer In combination with chemotherapy, Loder resulted in a median overall survival (OS) advantage of 9.3 months over chemotherapy alone (22.7 vs 13.4 months) Modi'in, Israel and New York, New York, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa"), a special purpose acquisition company, today announced it has entered into a business combination agreement with Silexion Ltd. ("Silexion"), a cli
- 13D/GSEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)
- 13D/GSEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)
- 13D/GSEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)
- 13D/GSEC Form SC 13G filed by Moringa Acquisition CorpSC 13G - Moringa Acquisition Corp (0001835416) (Subject)
- SECSEC Form 10-Q filed by Moringa Acquisition Corp10-Q - Moringa Acquisition Corp (0001835416) (Filer)
- 13D/GSEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)
- INSIDERSEC Form 4: Hudson Bay Capital Management Lp disposed of $4,253,473 worth of Class A Ordinary Shares (401,271 units at $10.60)4 - Moringa Acquisition Corp (0001835416) (Issuer)
- SECMoringa Acquisition Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - Moringa Acquisition Corp (0001835416) (Filer)
MACA FAQ
6 questionsWhat does Moringa Acquisition Corp do?
Moringa Acquisition Corp does not have significant operations. The company intends to acquire assets and businesses through a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It focuses on pursuing opportunities in technology-based businesses or industries in Israel. The company was incorporated in 2020 and is based in New York, New York.Where does MACA stock trade?
Moringa Acquisition Corp (MACA) is listed on NASDAQ.What sector and industry is MACA in?
Moringa Acquisition Corp operates in the Finance sector, Blank Checks industry.When did Moringa Acquisition Corp go public?
Moringa Acquisition Corp (MACA) completed its IPO in 2021.What companies are similar to MACA?
Notable peers in the same industry include CVII (Churchill Capital Corp VII), JWSM (Jaws Mustang Acquisition Corp.), HERA (FTAC Hera Acquisition Corp.), CPUH (Compute Health Acquisition Corp.), CONX (CONX Corp.). Compare MACA side-by-side with any of them on Quantisnow.How can I track MACA on Quantisnow?
Quantisnow aggregates Moringa Acquisition Corp's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MACA to receive live email and push alerts on every new disclosure.